Cargando…

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review

BACKGROUND: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has been studied, data reported so far are conflicting and critical consideration is needed before translation to the treatment of GC. METHODS: We performed a meta-analysis by using 20 eligible...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen, Chen, Jun-qiang, Liu, Jin-lu, Qin, Xin-gan, Huang, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524027/
https://www.ncbi.nlm.nih.gov/pubmed/23020798
http://dx.doi.org/10.1186/1471-230X-12-137
_version_ 1782253258542153728
author Wang, Zhen
Chen, Jun-qiang
Liu, Jin-lu
Qin, Xin-gan
Huang, Yuan
author_facet Wang, Zhen
Chen, Jun-qiang
Liu, Jin-lu
Qin, Xin-gan
Huang, Yuan
author_sort Wang, Zhen
collection PubMed
description BACKGROUND: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has been studied, data reported so far are conflicting and critical consideration is needed before translation to the treatment of GC. METHODS: We performed a meta-analysis by using 20 eligible studies to examine polymorphisms of ERCC1, GSTs, TS and MTHFR in predicting clinical outcomes (response rate, overall survival and toxicity) of GC patients treated with platinum/5-Fu-based chemotherapy. The association was measured using random/fixed effect odds ratios (ORs) or hazard ratios (HRs) combined with their 95% confidence intervals (CIs) according to the studies’ heterogeneity. Statistical analysis was performed with the software STATA 9.0 package. RESULTS: No significant association was found between response rate and genetic polymorphism in TS, MTHFR, ERCC1, GSTM1 and GSTP1. However, response rate was higher in GSTT1 (+) genotype compared with GSTT1 (−) genotype (T-/T+: OR=0.67, 95% CI: 0.47–0.97). With regard to long term outcomes, we could observe a significant longer overall survival in TS 3R/3R [(2R2R+2R3R)/3R3R: HR=1.29, 95% CI: 1.02–1.64] and GSTP1 GG/GA [(GG+AG)/AA: HR=0.51, 95% CI: (0.39, 0.67)] genotypes. In addition, significant association was demonstrated between toxicity and genetic polymorphism in TS, MTHFR and GSTP1 in included studies. CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy. Studies with large sample size using the method of multi-variant analyses may help us to give more persuasive data on the putative association in future.
format Online
Article
Text
id pubmed-3524027
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35240272012-12-18 Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review Wang, Zhen Chen, Jun-qiang Liu, Jin-lu Qin, Xin-gan Huang, Yuan BMC Gastroenterol Research Article BACKGROUND: Despite genetic polymorphism in response to platinum/5-Fu chemotherapy in gastric cancer (GC) has been studied, data reported so far are conflicting and critical consideration is needed before translation to the treatment of GC. METHODS: We performed a meta-analysis by using 20 eligible studies to examine polymorphisms of ERCC1, GSTs, TS and MTHFR in predicting clinical outcomes (response rate, overall survival and toxicity) of GC patients treated with platinum/5-Fu-based chemotherapy. The association was measured using random/fixed effect odds ratios (ORs) or hazard ratios (HRs) combined with their 95% confidence intervals (CIs) according to the studies’ heterogeneity. Statistical analysis was performed with the software STATA 9.0 package. RESULTS: No significant association was found between response rate and genetic polymorphism in TS, MTHFR, ERCC1, GSTM1 and GSTP1. However, response rate was higher in GSTT1 (+) genotype compared with GSTT1 (−) genotype (T-/T+: OR=0.67, 95% CI: 0.47–0.97). With regard to long term outcomes, we could observe a significant longer overall survival in TS 3R/3R [(2R2R+2R3R)/3R3R: HR=1.29, 95% CI: 1.02–1.64] and GSTP1 GG/GA [(GG+AG)/AA: HR=0.51, 95% CI: (0.39, 0.67)] genotypes. In addition, significant association was demonstrated between toxicity and genetic polymorphism in TS, MTHFR and GSTP1 in included studies. CONCLUSION: Polymorphisms of ERCC1, GSTs, TS and MTHFR were closely associated with clinical outcomes of GC patients treated with platinum/5-Fu-based chemotherapy. Studies with large sample size using the method of multi-variant analyses may help us to give more persuasive data on the putative association in future. BioMed Central 2012-09-29 /pmc/articles/PMC3524027/ /pubmed/23020798 http://dx.doi.org/10.1186/1471-230X-12-137 Text en Copyright ©2012 Wang; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Zhen
Chen, Jun-qiang
Liu, Jin-lu
Qin, Xin-gan
Huang, Yuan
Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
title Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
title_full Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
title_fullStr Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
title_full_unstemmed Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
title_short Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
title_sort polymorphisms in ercc1, gsts, ts and mthfr predict clinical outcomes of gastric cancer patients treated with platinum/5-fu-based chemotherapy: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524027/
https://www.ncbi.nlm.nih.gov/pubmed/23020798
http://dx.doi.org/10.1186/1471-230X-12-137
work_keys_str_mv AT wangzhen polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview
AT chenjunqiang polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview
AT liujinlu polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview
AT qinxingan polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview
AT huangyuan polymorphismsinercc1gststsandmthfrpredictclinicaloutcomesofgastriccancerpatientstreatedwithplatinum5fubasedchemotherapyasystematicreview